CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
2.38
1.28%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading сonditions
Spread 0.09
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026179 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026179%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003957 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003957%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

TherapeuticsMD Inc ESG Risk Ratings

High Medium Low Negligible

‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 2.35
Open* 2.37
1-Year Change* -51.23%
Day's Range* 2.33 - 2.38
52 wk Range 1.95-5.55
Average Volume (10 days) 15.94K
Average Volume (3 months) 470.95K
Market Cap 24.01M
P/E Ratio -100.00K
Shares Outstanding 10.58M
Revenue 1.95M
EPS -4.11
Dividend (Yield %) N/A
Beta 1.02
Next Earnings Date Apr 5, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Feb 29, 2024 2.35 0.08 3.52% 2.27 2.35 2.26
Feb 28, 2024 2.28 -0.03 -1.30% 2.31 2.36 2.23
Feb 27, 2024 2.32 0.12 5.45% 2.20 2.33 2.19
Feb 26, 2024 2.26 0.06 2.73% 2.20 2.26 2.20
Feb 23, 2024 2.21 0.01 0.45% 2.20 2.21 2.20
Feb 22, 2024 2.23 0.03 1.36% 2.20 2.23 2.20
Feb 21, 2024 2.23 0.02 0.90% 2.21 2.23 2.18
Feb 20, 2024 2.21 0.00 0.00% 2.21 2.21 2.20
Feb 16, 2024 2.22 0.00 0.00% 2.22 2.23 2.20
Feb 15, 2024 2.22 -0.02 -0.89% 2.24 2.24 2.19
Feb 14, 2024 2.24 0.04 1.82% 2.20 2.24 2.17
Feb 13, 2024 2.22 0.02 0.91% 2.20 2.23 2.19
Feb 12, 2024 2.22 0.03 1.37% 2.19 2.26 2.19
Feb 9, 2024 2.23 0.03 1.36% 2.20 2.24 2.20
Feb 8, 2024 2.21 0.03 1.38% 2.18 2.21 2.18
Feb 7, 2024 2.22 -0.01 -0.45% 2.23 2.23 2.16
Feb 6, 2024 2.24 0.01 0.45% 2.23 2.25 2.23
Feb 5, 2024 2.24 0.01 0.45% 2.23 2.25 2.21
Feb 2, 2024 2.23 -0.01 -0.45% 2.24 2.24 2.23
Feb 1, 2024 2.24 0.00 0.00% 2.24 2.24 2.23

TherapeuticsMD Events

Time (UTC) Country Event
Friday, April 5, 2024

Time (UTC)

10:59

Country

US

Event

Q4 2023 TherapeuticsMD Inc Earnings Release
Q4 2023 TherapeuticsMD Inc Earnings Release

Forecast

-

Previous

-
Monday, May 13, 2024

Time (UTC)

10:59

Country

US

Event

Q1 2024 TherapeuticsMD Inc Earnings Release
Q1 2024 TherapeuticsMD Inc Earnings Release

Forecast

-

Previous

-
Tuesday, June 25, 2024

Time (UTC)

12:00

Country

US

Event

TherapeuticsMD Inc Annual Shareholders Meeting
TherapeuticsMD Inc Annual Shareholders Meeting

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 69.963 2.573 64.8723 49.6469 16.0995
Revenue 69.963 2.573 64.8723 49.6469 16.0995
Cost of Revenue, Total 1.397 1.402 15.975 6.33459 2.73765
Gross Profit 68.566 1.171 48.8973 43.3124 13.3618
Total Operating Expense 68.772 82.15 220.413 210.91 146.32
Selling/General/Admin. Expenses, Total 57.903 80.748 192.964 174.113 115.989
Research & Development 0 0 10.4319 19.7922 27.2991
Depreciation / Amortization 1.04217 0.61279 0.29389
Operating Income 1.191 -79.577 -155.541 -161.263 -130.22
Interest Income (Expense), Net Non-Operating -28.581 -17.3822 -4.67783
Other, Net -0.117 0.272 0.59765 2.50011 2.28084
Net Income Before Taxes 1.074 -79.305 -183.524 -176.145 -132.617
Net Income After Taxes 1.074 -79.305 -183.524 -176.145 -132.617
Net Income Before Extra. Items 1.074 -79.305 -183.524 -176.145 -132.617
Net Income 111.997 -172.415 -183.524 -176.145 -132.617
Income Available to Common Excl. Extra. Items 1.074 -79.305 -183.524 -176.145 -132.617
Income Available to Common Incl. Extra. Items 111.997 -172.415 -183.524 -176.145 -132.617
Diluted Net Income 111.997 -172.415 -183.524 -176.145 -132.617
Diluted Weighted Average Shares 9.366 7.96 5.51297 4.92707 4.50053
Diluted EPS Excluding Extraordinary Items 0.11467 -9.96294 -33.2895 -35.7505 -29.467
Diluted Normalized EPS 1.12599 -9.96294 -33.0842 -33.7092 -29.467
Unusual Expense (Income) 9.472 0 0 10.0576
Total Extraordinary Items 110.923 -93.11
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 0.437 0.416 1.152 20.917 0.348
Revenue 0.437 0.416 1.152 20.917 0.348
Cost of Revenue, Total 0 0 -11.991 3.788 0.348
Gross Profit 0.437 0.416 13.143 17.129 0
Total Operating Expense 2.909 3.083 -65.856 41.664 15.205
Selling/General/Admin. Expenses, Total 2.781 3.056 2.458 36.764 14.575
Research & Development 1.112
Operating Income -2.472 -2.667 67.008 -20.747 -14.857
Interest Income (Expense), Net Non-Operating -0.045 -0.05 -4.909 0
Other, Net 0.103 0.407 -100.519 -3.569 -0.016
Net Income Before Taxes -2.414 -2.31 -33.511 -29.225 -14.873
Net Income After Taxes -2.414 -2.31 -33.221 -28.965 -14.873
Net Income Before Extra. Items -2.414 -2.31 -33.221 -28.965 -14.873
Net Income -2.414 -3.603 77.702 -28.965 112.281
Income Available to Common Excl. Extra. Items -2.414 -2.31 -33.221 -28.965 -14.873
Income Available to Common Incl. Extra. Items -2.414 -3.603 77.702 -28.965 112.281
Diluted Net Income -2.414 -3.603 77.702 -28.965 112.281
Diluted Weighted Average Shares 10.219 9.754 9.481 9.261 8.75
Diluted EPS Excluding Extraordinary Items -0.23623 -0.23683 -3.50396 -3.12763 -1.69977
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -0.23623 -0.23683 -2.85457 -3.12763 -1.69977
Unusual Expense (Income) 9.472 0
Total Extraordinary Items 0 -1.293 110.923 127.154
Depreciation / Amortization 0.128 0.027 0.282
Other Operating Expenses, Total -65.795
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 55.351 119.468 128.404 208.416 186.779
Cash and Short Term Investments 38.067 64.907 80.4858 160.83 161.613
Cash 38.067 64.907 80.4858 160.83 161.613
Total Receivables, Net 32.3817 24.396 11.0638
Accounts Receivable - Trade, Net 32.3817 24.396 11.0638
Total Inventory 7.99309 11.8607 3.26767
Prepaid Expenses 3.501 5.035 3.90368 5.99155 5.93925
Total Assets 90.458 169.472 181.61 265.986 211.984
Property/Plant/Equipment, Total - Net 7.658 9.057 11.5079 12.6169 0.47268
Property/Plant/Equipment, Total - Gross 10.103 11.028 13.2494 13.5857 1.02631
Accumulated Depreciation, Total -2.445 -1.971 -1.74145 -0.96882 -0.55363
Intangibles, Net 6.943 7.144 41.4446 44.4795 24.0927
Other Long Term Assets, Total 0.253 33.803 0.25312 0.47301 0.6393
Total Current Liabilities 46.839 252.891 59.2382 53.0048 41.0788
Accounts Payable 2.162 3.373 21.0683 19.1812 22.7438
Accrued Expenses 17.242 10.481 26.428 19.68 11.8724
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 27.435 50.768 11.7418 14.1437 6.46258
Total Liabilities 55.315 263.093 305.611 256.785 114.46
Total Long Term Debt 0 0 237.698 194.635 73.381
Total Equity 35.143 -93.621 -124.002 9.20112 97.5241
Preferred Stock - Non Redeemable, Net 0 0 0 0
Common Stock 0.009 0.009 0.29977 0.27118 0.24046
Additional Paid-In Capital 974.497 957.73 754.644 704.351 616.56
Retained Earnings (Accumulated Deficit) -939.363 -1051.36 -878.945 -695.421 -519.276
Total Liabilities & Shareholders’ Equity 90.458 169.472 181.61 265.986 211.984
Total Common Shares Outstanding 9.498 8.598 5.99531 5.42354 4.80925
Other Current Assets, Total 13.783 49.526 3.63972 5.33824 4.89544
Long Term Debt 237.698 194.635 73.381
Other Liabilities, Total 8.476 10.202 8.67548 9.14505
Note Receivable - Long Term 20.253 0
Current Port. of LT Debt/Capital Leases 0 188.269
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total Current Assets 17.441 19.613 24.735 55.351 87.478
Cash and Short Term Investments 10.166 13.729 17.248 38.067 27.08
Cash 10.166 13.729 17.248 38.067 27.08
Total Receivables, Net 3.134 1.038 2.041 32.157
Accounts Receivable - Trade, Net 32.157
Total Inventory 6.701
Prepaid Expenses 2.966 3.399 3.942 3.501 4.704
Total Assets 50.493 53.689 59.601 90.458 133.907
Property/Plant/Equipment, Total - Net 7.074 7.267 7.464 7.658 8.3
Property/Plant/Equipment, Total - Gross 9.577 9.751 9.928 10.103 11.296
Accumulated Depreciation, Total -2.503 -2.484 -2.464 -2.445 -2.996
Intangibles, Net 6.657 6.767 6.877 6.943 37.876
Other Long Term Assets, Total 0.254 0.254 0.253 0.253 0.253
Total Current Liabilities 14.512 14.364 19.336 46.839 174.071
Accounts Payable 0.696 1.508 2.326 2.162 13.383
Accrued Expenses 3.701 4.573 12.025 17.242 36.171
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 0 93.602
Other Current Liabilities, Total 10.115 8.283 4.985 27.435 30.915
Total Liabilities 22.441 22.492 27.577 55.315 182.178
Total Long Term Debt 0 0 0 0 0
Long Term Debt
Other Liabilities, Total 7.929 8.128 8.241 8.476 8.107
Total Equity 28.052 31.197 32.024 35.143 -48.271
Preferred Stock - Non Redeemable, Net 0 0 0
Common Stock 0.011 0.011 0.01 0.009 0.009
Additional Paid-In Capital 976.799 976.566 974.98 974.497 968.785
Retained Earnings (Accumulated Deficit) -948.758 -945.38 -942.966 -939.363 -1017.07
Total Liabilities & Shareholders’ Equity 50.493 53.689 59.601 90.458 133.907
Total Common Shares Outstanding 10.575 10.575 9.548 9.498 9.467
Other Current Assets, Total 1.175 1.447 1.504 13.783 16.836
Note Receivable - Long Term 19.067 19.788 20.272 20.253
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line 111.997 -172.415 -183.524 -176.145 -132.617
Cash From Operating Activities -4.078 -142.693 -159.47 -165.698 -106.812
Cash From Operating Activities 1.193 0.736 0.77262 0.41519 0.18141
Amortization 0.26955 0.19759 0.11247
Non-Cash Items -113.182 24.395 26.3279 23.8349 9.14785
Changes in Working Capital -4.086 4.591 -3.31624 -14.0003 16.3636
Cash From Investing Activities 223.479 -2.223 -1.59791 -23.9127 -21.4979
Capital Expenditures -0.355 -2.223 -1.59791 -23.8923 -21.3225
Other Investing Cash Flow Items, Total 223.834 0 -0.02042 -0.17541
Cash From Financing Activities -235.206 129.552 80.7243 188.827 162.787
Issuance (Retirement) of Stock, Net -14.505 184.67 31.9743 77.1399 91.574
Net Change in Cash -15.805 -15.364 -80.3439 -0.78336 34.4775
Cash Interest Paid 13.545 25.068 25.8492 17.7879 1.89017
Financing Cash Flow Items -1.269 -5.118 -1.25 -6.65227 -3.78692
Issuance (Retirement) of Debt, Net -219.432 -50 50 118.339 75
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -3.603 111.997 34.295 63.26 -49.021
Cash From Operating Activities -33.175 -4.078 -63.85 -44.93 -29.526
Cash From Operating Activities 0.027 1.193 3.181 2.146 0.329
Non-Cash Items -22.699 -113.182 -102.242 -113.152 21.546
Cash Interest Paid 0 13.545 8.371 9.137 5.364
Changes in Working Capital -6.9 -4.086 0.916 2.816 -2.38
Cash From Investing Activities 0 223.479 142.316 142.347 -0.212
Capital Expenditures 0 -0.355 -0.318 -0.287 -0.212
Cash From Financing Activities 1.106 -235.206 -105.258 -124.986 -5
Financing Cash Flow Items 1.106 -1.269 1.022 0 0
Issuance (Retirement) of Stock, Net -14.505 18.72 0.014
Issuance (Retirement) of Debt, Net 0 -219.432 -125 -125 -5
Net Change in Cash -32.069 -15.805 -26.792 -27.569 -34.738
Other Investing Cash Flow Items, Total 223.834 142.634 142.634

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

TherapeuticsMD Company profile

TherapeuticsMD
Industry: Proprietary & Advanced Pharmaceuticals

951 W Yamato Rd Ste 220
BOCA RATON
FLORIDA 33431-4440
US

Income Statement

  • Annual
  • Quarterly

News

Nvidia (NVDA) confronts high expectations for Q4 results

Nvidia is arguably the hottest company on the planet. The company reports its Q4 results after the closing bell on Wednesday, the 21st of February. We preview what to expect from Nvidia’s earnings and analyse the technicals of its stock price.

12:13, 20 February 2024

UK Bank Earnings: What to expect from Lloyds, Barclays and HSBC?

UK banks will be in the spotlight in the week ahead as the European earnings season continues

16:38, 16 February 2024

Is Big Tech behind the apparent bull market rally?

While the Magnificent Seven have dominated market momentum in recent months, it’s not true that they are the sole drivers of the recent rally in equity markets.

16:05, 8 February 2024

US Earnings Week Ahead: Walt Disney, Uber, and Pepsi Co.

The last of the Magnificent Seven have reported, delivering mixed results. Meanwhile, according to FactSet, the S&P 500 is set for negative earnings growth for Q4, with estimates for the next quarter also downgraded.

16:24, 2 February 2024

Bank of England preview: will updated projections show more cuts are expected in 2024?

Markets have no doubt that the BoE will keep its rate unchanged

15:43, 31 January 2024

Meta Platforms Q4 earnings forecast to surge on solid ad revenues

Meta Platforms (META) reports its Q4 results after Wall Street’s closing bell on February 1, 2024. We preview what to expect from the results and analyse the stock’s technicals.

15:33, 31 January 2024

Federal Reserve meeting preview: strong data is making it hard to justify cutting rates

Markets expect the Fed to keep rates unchanged as strong economic data continues

11:30, 30 January 2024

People also watch

XRP/USD

0.60 Price
-0.850% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 22:00 (UTC)
Spread 0.01168

Oil - Crude

80.34 Price
+2.790% 1D Chg, %
Long position overnight fee 0.0259%
Short position overnight fee -0.0478%
Overnight fee time 22:00 (UTC)
Spread 0.030

BTC/USD

61,575.50 Price
-0.230% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 106.00

US100

18,193.60 Price
+0.850% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 22:00 (UTC)
Spread 1.8

Still looking for a broker you can trust?

Join the 580.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading